Tim Bertram, PhD
Chief Executive Officer and Managing Director
Dr. Bertram is CEO and managing Director of RegenMed Therapeutics. Previously he served as Tengion’s Chief Scientific Officer from 2004 to 2014. Prior to joining Tengion, Dr. Bertram was senior scientific executive at Pfizer, SmithKline Beecham Pharmaceuticals, and Procter & Gamble Co; a faculty member at the University of Illinois; and a visiting scientist to the National Institutes of Health. Dr. Bertram has been a leadership-mentor to scientists in government, academics, and industry. His experience includes worldwide leadership of multidisciplinary scientific teams for the pharmaceutical industry, government and private foundations focusing on resolution of challenges in pharmaceutical productivity and defining industrial applications of advanced molecular, cellular and whole organism technologies for selecting optimal therapeutic candidates with experience in discovery, development and registration of small molecules, and cell-based therapy products. Organizational leadership activities have included Pharmaceutical R&D sites in both the US and Europe with responsibility for developing and setting Discovery and Development strategies. Most recently, Dr. Bertram was responsible for operational oversight of large discovery and development organizations in disciplines including genomics, proteomics, discovery, development, comparative medicine and business support groups to enable therapeutic agent development. His organizations have supported new medicine portfolios that included Gastrointestinal, CNS, Cancer, Respiratory, Infectious, Immunologic, Cardiovascular, Urology, Nephrology and Metabolic diseases with the preparation of regulatory submissions for agencies in major markets around the world. Dr. Bertram holds active academic appointments and industrial advisory positions at leading national and European educational institutions, International Society of Stem Cell Research, Tissue Engineering Regenerative Medical International Society Industrial Liaison Committee, Industrial Business Advisory Board and Industrial Advisory Committee of UCLA’s Bioengineering Department and industry. Dr. Bertram is a member of journal editorial boards for Tissue Engineering and, Regenerative Medicine. He has over 150 scientific communications and patents focusing on the cellular and molecular basis of diseases and cell therapeutic development. He has been directly involved with the commercialization of 8 products that today are changing the lives of many sick and ill patients.
Deepak Jain, PhD
Chief Operating Officer
Dr. Jain co-founded and joined RegenMedTX in 2015 as Chief Operating Officer and has over 33 years of experience in biotechnology, tissue engineering, cell therapy and regenerative medicine bioprocess research & development and GMP manufacturing. Before joining RegenMedTX, Dr. Jain was Senior Vice President of Bioprocess R&D and Technical Operations at Tengion responsible for bioprocess research, process development and clinical manufacturing of advanced regenerative medicine and cell therapy products including urinary bladder replacement and kidney regeneration. Prior to Tengion, Dr. Jain was the Executive Director of Process Development and Manufacturing Technical Support at Advanced Tissue Sciences responsible for development of human-based tissue engineered products for therapeutic applications in the skin, cartilage and cardiovascular areas. Dr. Jain has held several positions of increasing technical and management responsibility at Merck and Johnson & Johnson, leading the development of biotechnology products with a focus on recombinant proteins. Dr. Jain was instrumental in the development and manufacturing support of J&J’s multi-billion dollar product for the treatment of anemia. More recently, Dr. Jain was as a full-time consultant for Baxter Corporation responsible for establishing a commercial manufacturing facility overseas for a marketed recombinant protein. Dr. Jain is accomplished at directing product development from research to the clinic, process scale-up, technology transfers, GMP facility design, process validation and manufacturing of biotechnology-derived recombinant proteins and tissue engineered cell therapy and regenerative medicine products. He is highly experienced in regulatory CMC submissions for biologics, devices and combination products. Dr. Jain serves as the Chairman of Cell Therapy Ad hoc Advisory Panel for United States Pharmacopoeia and served as a member of USP’s Biologics & Biotechnology Expert Committee. Dr. Jain has also served as Chairman of the American Society for Testing and Materials Task Group on Preservation of Cells and Tissue Engineered Medical Product’s with Cells. Dr. Jain has over 70 publications, presentations and abstracts, two book chapters and many patents in the field biologics, tissue engineering, cell therapy and regenerative medicine. Dr. Jain received a PhD from the Indian Institute of Technology, Delhi in Biochemical Engineering.